Compare AbCellera Biologics Inc (ABCL) vs LTC Properties Inc (LTC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs LTC Properties Inc — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while LTC Properties Inc trades at $39.24 (market cap $2.01B). The key difference: AbCellera Biologics Inc is the larger of the two by market cap, and LTC Properties Inc pays a 5.81% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | LTC | |
|---|---|---|
Market Cap | $2.35B | $2.01B |
Sector | Health | Real Estate |
52-Week High | $8.12 | $40.36 |
52-Week Low | $2.78 | $33.98 |
Enterprise Value | $1.99B | $2.86B |
Dividend Yield | — | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
LTC Properties trades at $39.23, down 0.13% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.69, missing expectations of $0.72, but revenue grew to $263M in 2025. Analyst consensus is mixed with 27% buy ratings, while recent news highlights dividend declarations and a $54M SHOP acquisition, reinforcing its focus on senior housing investments.
Outlook remains supported by demographic trends in senior housing, though earnings misses and high debt levels pose risks. The stock offers a monthly dividend, but investors face headwinds from execution challenges in shifting to SHOP strategy and interest rate sensitivity due to substantial leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
